Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Pancreatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Colorectal Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Lymphoma, Follicular 3Kidney Neoplasms 3Cholangiocarcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × durvalumab × Clear all
NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Celgene

Phase 1/2 Completed
56 enrolled 38 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡